The N.C. Policy Collaboratory based at UNC will receive $29 million to study treatment, community testing and prevention of COVID-19 as part of a $1.5 billion coronavirus relief package. read more
As national attention to the promising antiviral drug remdesivir grows this week, the Ralph Baric lab in UNC’s Gillings School of Global Public Health is in the spotlight again. read more
Chancellor Kevin M. Guskiewicz has announced the establishment of a UNC COVID-19 Research Accelerator Fund to provide support to Carolina’s research teams focused on COVID-19 testing, treatment and prevention. read more
The interim president of the UNC System said that he expects Carolina and the system’s other higher education institutions to reopen classrooms and laboratories in the fall. read more
The organization that supports UNC graduate and professional students has reached out to University administration for special aid due to conditions brought on by the COVID-19 pandemic and the shutdown of UNC operations. read more
Carolina was the highest ranked U.S. university in the world for coronavirus research in early April, based on how often other researchers cited articles written by the University’s faculty members. read more
The plight of UNC graduate students facing uncertain futures due to the COVID-19 pandemic’s impact on ability to work and on the economy has spilled out in a demands-filled letter to University officials. read more
The Rapidly Emerging Antiviral Drug Development Initiative will adopt extreme open science methods — sharing drug discovery progress in real time so that as many people as possible can benefit. read more
Scientists in Ralph Baric’s lab at UNC are playing a key role in the development and testing of a new drug, called EIDD-2801, that could change the way doctors treat COVID-19. read more
UNC Health CEO Dr. Wesley Burks reported the COVID-19 Response Fund had received more than $820,000 in gifts in its first two weeks from individual and corporate donors. read more